Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Yabao Pharmaceutical Group Co EV-to-EBITDA?
Yabao Pharmaceutical Group CoSHSE:600351 +5.14%74 EV-to-EBITDA is 7.57 as of Sep. 21, 2026, which is 63% below its 10-year median of 20.57. GuruFocus rates SHSE:600351 with a GF Score™ of 74/100 and a GF Value™ of ¥5.68 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 745 Drug Manufacturers companies, Yabao Pharmaceutical Group Co ranks better than 72.08% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Yabao Pharmaceutical Group Co's enterprise value is ¥3,866 Mil.
Yabao Pharmaceutical Group Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was ¥510 Mil. Therefore, Yabao Pharmaceutical Group Co's EV-to-EBITDA for today is 7.57.
The historical rank and industry rank for Yabao Pharmaceutical Group Co's EV-to-EBITDA or its related term are showing as below:
SHSE:600351'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -333.48 Med: 20.57 Max: 84.17
Current: 7.57
During the past 13 years, the highest EV-to-EBITDA of Yabao Pharmaceutical Group Co was 84.17. The lowest was -333.48. And the median was 20.57.
SHSE:600351's EV-to-EBITDA is ranked better than 72.08% of 745
companies
in the Drug Manufacturers industry
Industry Median: 12.56
vs SHSE:600351: 7.57
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Yabao Pharmaceutical Group Co (SHSE:600351) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Yabao Pharmaceutical Group Co's PE Ratio (TTM) for today is calculated as:
Yabao Pharmaceutical Group Co's share price for today is ¥6.95.
Yabao Pharmaceutical Group Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.467.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Yabao Pharmaceutical Group Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Yabao Pharmaceutical Group Co EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Yabao Pharmaceutical Group Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Yabao Pharmaceutical Group Co's EV-to-EBITDA falls into.
Yabao Pharmaceutical Group Co's current Enterprise Value is ¥3,866 Mil.
Yabao Pharmaceutical Group Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥510 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Yabao Pharmaceutical Group Co (SHSE:600351) has a EV-to-EBITDA of 7.57 as of Sep. 21, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Yabao Pharmaceutical Group Co. This is 63% below median its historical median of 20.57. According to the industry distribution chart, Yabao Pharmaceutical Group Co ranks #208 out of 745 companies in the Drug Manufacturers industry, placing it in the top 27.9%.
Is Yabao Pharmaceutical Group Co's EV-to-EBITDA too high?
Yabao Pharmaceutical Group Co's current EV-to-EBITDA of 7.57 is 63% below median its 10-year median of 20.57. The Drug Manufacturers industry median EV-to-EBITDA is 12.56. Yabao Pharmaceutical Group Co's value of 7.57 is 39.7% below this industry median. Based on the distribution chart, Yabao Pharmaceutical Group Co ranks #208 out of 745 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Yabao Pharmaceutical Group Co has a GF Score™ of 74/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Yabao Pharmaceutical Group Co's EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Yabao Pharmaceutical Group Co ranks #208 out of 745 companies for EV-to-EBITDA. This puts Yabao Pharmaceutical Group Co in the upper half of its industry. The industry median EV-to-EBITDA is 12.56. Yabao Pharmaceutical Group Co's value of 7.57 is 39.7% below this benchmark. While the company's 10-year median is 20.57 vs. the industry median of 12.56, Yabao Pharmaceutical Group Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.56, based on 745 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Yabao Pharmaceutical Group Co's current EV-to-EBITDA of 7.57 is 39.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Yabao Pharmaceutical Group Co. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Yabao Pharmaceutical Group Co's current EV-to-EBITDA is 7.57, which is 63% below median its own 10-year median of 20.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Yabao Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Yabao Pharmaceutical Group Co (SHSE:600351) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥5.68, compared to a current price of ¥6.95 — trading 22.4% above its estimated fair value. The current EV-to-EBITDA is 7.57, which is 63% below median its 10-year median of 20.57 and 39.7% below the Drug Manufacturers industry median of 12.56. Yabao Pharmaceutical Group Co's overall GF Score™ is 74/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Yabao Pharmaceutical Group Co (SHSE:600351), the current EV-to-EBITDA is 7.57 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Yabao Pharmaceutical Group Co (SHSE:600351) Overvalued in 2026?
Based on GuruFocus' analysis, Yabao Pharmaceutical Group Co stock appears to be overvalued.
The current stock price of ¥6.95 is trading 22.4% above its estimated GF Value™ of ¥5.68.
GuruFocus considers Yabao Pharmaceutical Group Co to be Modestly Overvalued.
Key valuation signals for SHSE:600351:
EV-to-EBITDA: 7.57 (63% below median its 10-year median of 20.57)
GF Value™: ¥5.68 vs. price of ¥6.95 (22.4% above fair value)
Industry Position: 39.7% below the Drug Manufacturers median (#208 of 745)
No single metric tells the full story. See the SHSE:600351 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Yabao Pharmaceutical Group Co Ltd is engaged in the manufacture and operation of western and Chinese medicines, APIs, health care products, packing materials for medicine, and also engages in the planting and processing of medicinal herbs.
74GF Score
Get the complete analysis for SHSE:600351
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600351 has been successfully added to your 
